PAG
VKTX icon

Private Advisor Group’s Viking Therapeutics VKTX Stock Holding History

Private Advisor Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,900
Closed -$29.8K – 2699
2025
Q2 		$29.8K Buy
+3,900
New +$103K ﹤0.01% 2380

Other funds holding VKTX

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
IFWM
Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return
LA
LBP AM Paris, France $10B AUM 43.88% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
MASM
MH & Associates Securities Management Carlsbad, California $112M AUM

Private Advisor Group's VKTX Position: Q2 2026 in Review

Private Advisor Group increased its Viking Therapeutics (VKTX) stake by 1.6% in Q2 2026, buying an estimated $4.26K and bringing the position to 8,383 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #2059.

Private Advisor Group first reported a position in VKTX in Q2 2020 and has held it in 10 quarters since. The position peaked at $575K in Q3 2024. 108 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Private Advisor Group held 8,383 shares of Viking Therapeutics worth $327K as of Q2 2026.
  • Private Advisor Group bought 132 Viking Therapeutics shares in Q2 2026, an estimated $4.26K.
  • Viking Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #2059 holding.
  • Private Advisor Group first reported a position in Viking Therapeutics in Q2 2020 and has held it in 10 quarters since.
  • Private Advisor Group's Viking Therapeutics position peaked at $575K in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.